EI

251.8

-0.32%↓

SAN

81.4

+0.15%↑

SHL.DE

45.95

-0.2%↓

ARGX

550.8

-1.18%↓

PHIA

23.17

+0.87%↑

EI

251.8

-0.32%↓

SAN

81.4

+0.15%↑

SHL.DE

45.95

-0.2%↓

ARGX

550.8

-1.18%↓

PHIA

23.17

+0.87%↑

EI

251.8

-0.32%↓

SAN

81.4

+0.15%↑

SHL.DE

45.95

-0.2%↓

ARGX

550.8

-1.18%↓

PHIA

23.17

+0.87%↑

EI

251.8

-0.32%↓

SAN

81.4

+0.15%↑

SHL.DE

45.95

-0.2%↓

ARGX

550.8

-1.18%↓

PHIA

23.17

+0.87%↑

EI

251.8

-0.32%↓

SAN

81.4

+0.15%↑

SHL.DE

45.95

-0.2%↓

ARGX

550.8

-1.18%↓

PHIA

23.17

+0.87%↑

Search

Orion Oyj (Class B)

Abierto

66.55 0.38

Resumen

Variación precio

24h

Actual

Mínimo

66.05

Máximo

66.8

Métricas clave

By Trading Economics

Ingresos

119M

180M

Ventas

62M

417M

P/B

Media del Sector

26.431

34.393

BPA

0.59

Rentabilidad por dividendo

2.33

Margen de beneficio

43.289

Empleados

3,700

EBITDA

202M

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

2.33%

2.54%

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

1.1B

10B

Apertura anterior

66.17

Cierre anterior

66.55

Orion Oyj (Class B) Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

11 ago 2025, 17:49 UTC

Principales Movimientos del Mercado

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 ago 2025, 17:18 UTC

Principales Movimientos del Mercado

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 ago 2025, 16:25 UTC

Ganancias

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 ago 2025, 23:50 UTC

Charlas de Mercado

Nikkei May Rise as Yen Weakens -- Market Talk

11 ago 2025, 23:42 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

11 ago 2025, 23:42 UTC

Charlas de Mercado

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 ago 2025, 23:36 UTC

Charlas de Mercado

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 ago 2025, 23:32 UTC

Charlas de Mercado

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 ago 2025, 23:02 UTC

Charlas de Mercado

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 ago 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

11 ago 2025, 20:37 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 ago 2025, 20:37 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 ago 2025, 20:37 UTC

Ganancias
Adquisiciones, fusiones, absorciones

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 ago 2025, 20:22 UTC

Ganancias

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 ago 2025, 20:22 UTC

Ganancias

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 ago 2025, 20:22 UTC

Ganancias

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 ago 2025, 20:22 UTC

Ganancias

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 ago 2025, 20:22 UTC

Ganancias

Exodus Movement 2Q Rev $25.8M >EXOD

11 ago 2025, 20:14 UTC

Charlas de Mercado

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 ago 2025, 19:12 UTC

Charlas de Mercado

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 ago 2025, 18:56 UTC

Charlas de Mercado

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 ago 2025, 18:31 UTC

Charlas de Mercado

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 ago 2025, 17:43 UTC

Charlas de Mercado

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 ago 2025, 17:28 UTC

Charlas de Mercado

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 ago 2025, 17:16 UTC

Charlas de Mercado

Commodity Longs Fall to 11-Month Low -- Market Talk

11 ago 2025, 16:42 UTC

Adquisiciones, fusiones, absorciones

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 ago 2025, 16:27 UTC

Adquisiciones, fusiones, absorciones

BBVA Says Sabadell Offer Remains in Effect

11 ago 2025, 16:26 UTC

Adquisiciones, fusiones, absorciones

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 ago 2025, 16:25 UTC

Adquisiciones, fusiones, absorciones

Banco de Sabadell Announced TSB Sale on July 1

11 ago 2025, 16:25 UTC

Adquisiciones, fusiones, absorciones

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Comparación entre iguales

Cambio de precio

Orion Oyj (Class B) Esperado

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Orion Oyj (Class B)

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. In addition, the company provides veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; APIs for generic compounds and proprietary products, as well as contract manufacturing services; and markets and sells veterinary drugs manufactured by other international companies. It has partnership with Propeller Health to connect the Easyhaler(R) product portfolio; collaboration and option to license agreement with Abilita Therapeutics to develop innovative antibody therapeutics; and a research collaboration and license agreement with Amneal Pharmaceuticals, Inc. to commercialize Amneal's generic products. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.